Overview

Uzatresgene autoleucel [uza-cel; formerly ADP-A2M4CD8] T-cell therapy is our first "next-generation" therapy and is directed to MAGE-A4, a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. What differentiates this therapy from our ADP-A2M4 T cells is that these cells also express the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4. Preclinical data indicate that co-expression of CD8α may broaden the immune response against solid tumors and increase anti-tumor activity by leveraging CD4⁺ cells into CD8⁺ killer or cytotoxic T‑cells while retaining their CD4⁺ helper function.

Adaptimmune recently entered into a clinical collaboration and exclusive option and license agreement with Galapagos NV to develop uza-cel for head & neck cancer and potentially all additional solid tumor indications using Galapagos’ decentralized cell manufacturing platform.